Back to search results
Active
Last updated: November 21, 2025

Tamsulosin

Flomax

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery type:
    • Oral
  • Intended Duration:
    • Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/researcher(s): Centro Universitario FMABC
Details
  • API: Tamsulosin
  • Target: Adrenoceptor
  • Mechanism of Action:
    • Inhibition of Sperm Motility
    • Other
  • Inactive Materials: Not Yet Determined
  • Regimen: Not Yet Determined
  • MPT: Not Potential MPT
  • Promising Attributes: Tamsulosin has SRA approval for other indications. It may offer an on-demand option to male users with a desirable safety and side effect profile.
Product Status

Developer Confirms Active Research

History

Tamsulosin is an FDA-approved product (marketed as Flomax) used to treat benign prostatic hyperplasia. It was briefly evaluated for a contraceptive indication, including small scale human studies. Centro Universitario FMABC confirmed active evaluation in 2023.

Publications

Additional Information